Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non‐alcoholic fatty liver disease - Shiffman, Mitchell; Freilich, Bradley; Vuppalanchi, Raj; Watt, Kymberly; Chan, Jean L.; Spada, Al; Hagerty, David T.; Schiff, Eugene (Alimentary pharmacology & therapeutics, 2019)
Keywords: Adult; Aged; Alanine Transaminase - blood; Apoptosis; Caspase 3 - metabolism; Caspase inhibitors; Caspase-3; Cirrhosis; Clinical trials; Cytokeratin; Double-Blind Method; Fatty liver; Female; Hepatitis; Humans; Inflammation; Keratin-18 - metabolism; Liver - pathology; Liver cirrhosis; Liver Cirrhosis - drug therapy; Liver Cirrhosis - pathology; Liver diseases; Male; Middle Aged; Non-alcoholic Fatty Liver Disease - drug therapy; Non-alcoholic Fatty Liver Disease - pathology; Pentanoic Acids - administration & dosage; Pentanoic Acids - pharmacology; Randomised Clinical Trial